Abstract
RNA interference (RNAi) is a powerful endogenous process initiated by short double stranded RNAs, which results in sequence-specific posttranscriptional gene silencing. The ability to block the expression of any disease-causing or disease-related protein emphasizes the huge therapeutic potential of this technology. In a clinical setting, however, the use of RNAi-based therapeutics is limited by their short serum half lives and poor uptake into cells. In this review, we provide an overview of recent patents in the field of short interfering RNA (siRNA) delivery and discuss recent progress in the development of efficient siRNA delivery vehicles enhancing the pharmacokinetic properties of RNAi-based therapeutics and promoting cellular uptake.
Keywords: RNA interference, specific knock-down, non-targeted delivery, targeted delivery, cell-specific ligands
Recent Patents on Anti-Cancer Drug Discovery
Title: Targeted Delivery of Short Interfering RNAs - Strategies for In Vivo Delivery
Volume: 4 Issue: 1
Author(s): Ulrich Wullner, Inga Neef, Mehmet K. Tur and Stefan Barth
Affiliation:
Keywords: RNA interference, specific knock-down, non-targeted delivery, targeted delivery, cell-specific ligands
Abstract: RNA interference (RNAi) is a powerful endogenous process initiated by short double stranded RNAs, which results in sequence-specific posttranscriptional gene silencing. The ability to block the expression of any disease-causing or disease-related protein emphasizes the huge therapeutic potential of this technology. In a clinical setting, however, the use of RNAi-based therapeutics is limited by their short serum half lives and poor uptake into cells. In this review, we provide an overview of recent patents in the field of short interfering RNA (siRNA) delivery and discuss recent progress in the development of efficient siRNA delivery vehicles enhancing the pharmacokinetic properties of RNAi-based therapeutics and promoting cellular uptake.
Export Options
About this article
Cite this article as:
Wullner Ulrich, Neef Inga, Tur K. Mehmet and Barth Stefan, Targeted Delivery of Short Interfering RNAs - Strategies for In Vivo Delivery, Recent Patents on Anti-Cancer Drug Discovery 2009; 4 (1) . https://dx.doi.org/10.2174/157489209787002506
DOI https://dx.doi.org/10.2174/157489209787002506 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Histotype in Non-Small Cell Lung Cancer Therapy and Staging: The Emerging Role of an Old and Underrated Factor
Current Respiratory Medicine Reviews Amino Acid Transporter-Targeted Radiotracers for Molecular Imaging in Oncology
Current Medicinal Chemistry Structural and Functional Characterization of the Proteins Responsible for N<sup>6</sup>-Methyladenosine Modification and Recognition
Current Protein & Peptide Science Synthetic Approaches to Various Class of Topoisomerase II Inhibitors
Mini-Reviews in Organic Chemistry Role of Infrared Spectroscopy and Imaging in Cancer Diagnosis
Current Medicinal Chemistry FAK and Interacting Proteins as Therapeutic Targets in Pancreatic Cancer
Anti-Cancer Agents in Medicinal Chemistry Developments in Targeted Therapy of Advanced Gastrointestinal Stromal Tumors
Recent Patents on Anti-Cancer Drug Discovery 3D Culture Modelling: An Emerging Approach for Translational Cancer Research in Sarcomas
Current Medicinal Chemistry Antiproliferative and Genotoxic Action of an Underexploited Organoteluran Derivative on Sarcoma 180 Cells
Anti-Cancer Agents in Medicinal Chemistry Xeno-Cannibalism as an Exacerbation of Self-Cannibalism: A Possible Fruitful Survival Strategy for Cancer Cells
Current Pharmaceutical Design Clinical Pharmacology of Cyclophosphamide and Ifosfamide
Current Drug Therapy Molecular Aspects of Resistance to Biological and Non-Biological Drugs and Strategies to Overcome Resistance in Colorectal Cancer
Current Medicinal Chemistry Antibiotics with Antiviral and Anti-Inflammatory Potential Against Covid-19: A Review
Current Reviews in Clinical and Experimental Pharmacology Review of the Biological Activity of Maslinic Acid
Current Drug Targets The Safety and Efficacy of Parathyroid Hormone (PTH) as a Biological Response Modifier for the Enhancement of Bone Regeneration
Current Drug Safety Mouse Induced Glioma-Initiating Cell Models and Therapeutic Targets
Anti-Cancer Agents in Medicinal Chemistry The Human Glioma-Associated Oncogene Homolog 1 (GLI1) Family of Transcription Factors in Gene Regulation and Diseases
Current Genomics Microenvironmental Regulation of Cancer Stem Cell Phenotypes
Current Stem Cell Research & Therapy Clinical Trials with Oncolytic Adenovirus in China
Current Cancer Drug Targets Adipose-Derived Stromal/Stem Cells (ASC) in Regenerative Medicine: Pharmaceutical Applications
Current Pharmaceutical Design